Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Expands By 294.2%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 225,242 shares, a growth of 294.2% from the January 15th total of 57,139 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average daily volume of 5,452,621 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 5,452,621 shares, the short-interest ratio is currently 0.0 days. Approximately 1.7% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new stake in Genenta Science during the 3rd quarter worth about $41,000. Norges Bank purchased a new stake in shares of Genenta Science in the fourth quarter worth about $337,000. Finally, Eurizon Capital SGR S.p.A. acquired a new stake in Genenta Science during the fourth quarter worth about $536,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genenta Science in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Genenta Science has a consensus rating of “Sell”.

Genenta Science Trading Down 4.3%

Shares of NASDAQ GNTA traded down $0.04 during midday trading on Wednesday, reaching $0.88. The company had a trading volume of 93,161 shares, compared to its average volume of 2,224,074. Genenta Science has a 1 year low of $0.71 and a 1 year high of $10.00. The business’s 50-day simple moving average is $1.37 and its 200 day simple moving average is $2.48.

Genenta Science (NASDAQ:GNTA) last released its earnings results on Friday, October 10th. The company reported ($0.10) earnings per share (EPS) for the quarter. On average, analysts forecast that Genenta Science will post -0.93 earnings per share for the current year.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.